Xeris Biopharma Holdings, Inc. (XERS): R&D Expense
$31.16M
Year ended 2025-12-31
$34.81M
Trailing 12 months to 2026-06-30
+14.1%
3-year compound annual growth
+8.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.16M | +21.9% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $25.56M | +14.4% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $22.34M | +6.6% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $20.97M | -16.7% | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | $25.16M | +20.3% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $20.92M | n/a | 2022-03-11, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $31.16M | +21.9% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $95.14M | -14.6% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $9.58M | +4.4% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $19.33M | +390.4% |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $81.18M | +278.9% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $285.20M | -18.1% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
Compare XERS, IRWD, EOLS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗